×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
BrainStorm Cell Therapeutics 'Committed' to NurOwn Despite Setbacks, Says Success in ALS 'Critical'
Precision Medicine Online
Lindborg said BrainStorm is committed to continuing to develop NurOwn in ALS and that the company views the stem cell therapy as essential to...
1 month ago
Brainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
KELOLAND.com
NEW YORK, July 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell...
2 days ago
The Life Sciences Report Asks If It Is Time to Go Long on BrainStorm Cell Therapeutics
Yahoo News Singapore
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics Inc. , including the science, the Phase 2 data...
3 days ago
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
GuruFocus
PR NewswireNEW YORK, April 8, 2024 A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern TimeNEW YORK, April 8, 2024 /PRNewswi.
2 days ago
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
PR Newswire
(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a...
4 months ago
Windtree Therapeutics (NASDAQ:WINT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Critical Contrast
Defense World
Read Windtree Therapeutics (NASDAQ:WINT) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Critical Contrast at Defense World.
1 day ago
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
MarketWatch
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a...
3 weeks ago
FDA meets with BrainStorm Cell Therapeutics to discuss NurOwn for ALS
Pharmaceutical Technology
BrainStorm Cell Therapeutics's NurOwn is approaching the conclusion of a three-year regulatory journey that commenced in February 2021 when...
5 months ago
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for ...
BioSpace
The meeting is scheduled to take place on December 6, 2023. Brainstorm will discuss plans for a Special Protocol Assessment (SPA) with the FDA...
5 months ago
After knock back, BrainStorm aligns with FDA on ph. 3 ALS trial
Fierce Biotech
BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis (ALS). A piece of the latest...
4 weeks ago